Shares of Fresenius Medical Care AG (ETR:FME – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of €36.90 ($40.11) and traded as high as €39.01 ($42.40). Fresenius Medical Care shares last traded at €38.77 ($42.14), with a volume of 342,136 shares traded.
Fresenius Medical Care Price Performance
The stock has a market cap of $11.60 billion, a price-to-earnings ratio of 21.85, a P/E/G ratio of 0.42 and a beta of 0.86. The company has a 50 day simple moving average of €36.48 and a 200-day simple moving average of €36.93. The company has a current ratio of 1.46, a quick ratio of 0.80 and a debt-to-equity ratio of 77.56.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Stories
- Five stocks we like better than Fresenius Medical Care
- 3 Tickers Leading a Meme Stock Revival
- Texas Roadhouse Stock Steering for New Highs This Year
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Use the MarketBeat Excel Dividend Calculator
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.